Markees T G, Phillips N E, Gordon E J, Noelle R J, Shultz L D, Mordes J P, Greiner D L, Rossini A A
Diabetes Division, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.
J Clin Invest. 1998 Jun 1;101(11):2446-55. doi: 10.1172/JCI2703.
Treatment of C57BL/6 mice with one transfusion of BALB/c spleen cells and anti-CD154 (anti-CD40-ligand) antibody permits BALB/c islet grafts to survive indefinitely and BALB/c skin grafts to survive for approximately 50 d without further intervention. The protocol induces long-term allograft survival, but the mechanism is unknown. We now report: (a) addition of thymectomy to the protocol permitted skin allografts to survive for > 100 d, suggesting that graft rejection in euthymic mice results from thymic export of alloreactive T cells. (b) Clonal deletion is not the mechanism of underlying long-term graft survival, as recipient thymectomized mice were immunocompetent and harbor alloreactive T cells. (c) Induction of skin allograft acceptance initially depended on the presence of IFN-gamma, CTLA4, and CD4(+) T cells. Addition of anti-CTLA4 or anti-IFN-gamma mAb to the protocol was associated with prompt graft rejection, whereas anti-IL-4 mAb had no effect. The role of IFN-gamma was confirmed using knockout mice. (d) Graft survival was associated with the absence of IFN-gamma in the graft. (e) Long-term graft maintenance required the continued presence of CD4(+) T cells. The results suggest that, with modification, our short-term protocol may yield a procedure for the induction of long-term graft survival without prolonged immunosuppression.
用一次BALB/c脾细胞输血和抗CD154(抗CD40配体)抗体处理C57BL/6小鼠,可使BALB/c胰岛移植长期存活,BALB/c皮肤移植在无需进一步干预的情况下存活约50天。该方案可诱导同种异体移植长期存活,但其机制尚不清楚。我们现在报告:(a)在该方案中加入胸腺切除术可使皮肤同种异体移植存活超过100天,这表明正常胸腺小鼠中的移植排斥反应是由同种异体反应性T细胞从胸腺输出所致。(b)克隆清除不是长期移植存活的潜在机制,因为接受胸腺切除的受体小鼠具有免疫活性且含有同种异体反应性T细胞。(c)皮肤同种异体移植接受的诱导最初依赖于IFN-γ、CTLA4和CD4(+) T细胞的存在。在该方案中加入抗CTLA4或抗IFN-γ单克隆抗体与移植迅速排斥相关,而抗IL-4单克隆抗体则无作用。使用基因敲除小鼠证实了IFN-γ的作用。(d)移植存活与移植中缺乏IFN-γ相关。(e)长期移植维持需要CD4(+) T细胞的持续存在。结果表明,经过改进,我们的短期方案可能产生一种无需长期免疫抑制即可诱导长期移植存活的方法。